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Introduction. The relation between minute ventilation (VE) and carbon dioxide production (VCO2) can be characterised by the
instantaneous ratio of ventilation to carbon dioxide production, the ventilatory equivalent for CO2 (VEqCO2). We hypothesised
that the time taken to achieve the lowest VEqCO2 (time to VEqCO2 nadir) may be a prognostic marker in patients with chronic
heart failure (CHF). Methods. Patients and healthy controls underwent a symptom-limited, cardiopulmonary exercise test (CPET)
on a treadmill to volitional exhaustion. Results. 423 patients with CHF (mean age 63 ± 12 years; 80% males) and 78 healthy
controls (62% males; age 61± 11 years) were recruited. Time to VEqCO2 nadir was shorter in patients than controls (327± 204 s
versus 514± 187 s; P = 0.0001). Univariable predictors of all-cause mortality included peak oxygen uptake (X2 = 53.0), VEqCO2
nadir (X2 = 47.9), and time to VEqCO2 nadir (X2 = 24.0). In an adjusted Cox multivariable proportional hazards model, peak
oxygen uptake (X2 = 16.7) and VEqCO2 nadir (X2 = 17.9) were themost significant independent predictors of all-cause mortality.
Conclusion. The time to VEqCO2 nadir was shorter in patients with CHF than in normal subjects and was a predictor of subsequent
mortality.
1. Introduction
Cardiopulmonary exercise testing (CPET) is used to stratify
risk in patients with cardiorespiratory disease [1]. In patients
with chronic heart failure (CHF), the normal linear relation
between ventilation (VE) and carbon dioxide production
(VCO2) is maintained, but the slope of the relation is
greater than normal, so that, for a given volume of carbon
dioxide production, the ventilatory response is greater [2–6].
Another way of characterising the relation between minute
ventilation and carbon dioxide production is the instanta-
neous ratio of ventilation to carbon dioxide production, the
ventilatory equivalent for CO2 (VEqCO2). Recently, we have
shown that the lowest VEqCO2 (VEqCO2 nadir) provides
greater prognostic value than other CPET-derived variables
in patients with suspected CHF [7]. Other studies have
reported that the lowest VEqCO2 has similar prognostic
power to the VE/VCO2 slope derived from the whole of
exercise [8].
During an incremental CPET, as exercise intensity
increases, both VCO2 and VE increase linearly. However,
VEqCO2 falls at the onset of exercise, possibly due to a
reduction in dead space ventilation. Beyond the ventilatory
compensation point (VCP), lactic acid production causes an
increase in ventilation relative to carbon dioxide production,
and thus the VEqCO2 rises. Although patients with CHF
have the same pattern of VEqCO2 during exercise as normal
subjects, with more severe heart failure, the increase in
VEqCO2 towards the end of exercise becomes more marked
[9]. In the most severely aﬀected patients, VEqCO2 increases
from the start of exercise [9]. We hypothesised that the time
taken to reach VEqCO2 nadir would be shorter in patients
with CHF compared to healthy controls and thus may be an
important prognostic indicator.
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2. Methods
The Hull and East Riding Ethics Committee approved
the study, and all patients provided informed consent.
We recruited consecutive patients referred to a commu-
nity heart failure clinic with symptoms of breathlessness
(NYHA functional class II-III) who were found to have
left ventricular systolic dysfunction on investigation. Clinical
information obtained included past medical history and
drug and smoking history. Clinical examination included
assessment of body mass index (BMI), heart rate, rhythm,
and blood pressure. Patients were excluded if they were
unable to exercise because of noncardiac limitations (such as
osteoarthritis) or had significant respiratory disease (defined
as a predicted FEV1 < 70%).
Heart failure was defined as the presence of current
symptoms of HF, or a history of symptoms controlled
by ongoing therapy, and impaired left ventricular systolic
function. Left ventricular function was determined from 2D
echocardiography which was carried out by one of three
trained operators. Left ventricular function was assessed by
estimation on a scale of normal, mild, mild-to-moderate,
moderate, moderate-to-severe, and severe impairment and
was assessed by a second operator blind to the assessment
of the first; where there was disagreement on the severity of
left ventricular (LV) dysfunction, the echocardiogram was
reviewed jointly with the third operator and a consensus
reached. Where possible, left ventricular ejection fraction
(LVEF) was calculated using the Simpson’s formula from
measurements of end-diastolic and end-systolic volumes on
apical 2D views, following the guidelines of Schiller and
colleagues [10], and LVSD was diagnosed if LVEF was≤45%.
When LVEF could not be calculated, LVSD was diagnosed
if LVEF ≤45 or there was at least “mild-to-moderate”
impairment.
Patients underwent a symptom-limited, maximal CPET
on a treadmill using the Bruce protocol modified by the
addition of a Stage 0 (2.74 km·h−1 and 0% gradient) at the
onset of exercise. Metabolic gas exchange was measured with
an Oxycon Delta metabolic cart (VIASYS Healthcare Inc.,
Philadelphia, PA, USA). Peak oxygen uptake (pVO2) was
calculated as the average VO2 for the final 30 s of exercise.
The ventilatory anaerobic threshold (AT) was calculated by
the V-slope method [11]. The gradient of the relationship
between VE and VCO2 (VE/VCO2 slope) was calculated by
linear regression analysis using data acquired from the whole
test. The VEqCO2 relation was plotted from start to the
finish of exercise. Each consecutive 30-second reading was
averaged, and the lowest point was defined as the VEqCO2
nadir [7]. The time taken to reach the VEqCO2 nadir was
reported in seconds (s). The peak respiratory exchange ratio
(pRER) was calculated as the mean VCO2/VO2 ratio for
the final 30 s of exercise. For comparative purposes, we also
included a healthy control group who had no evidence of
cardiac, respiratory, or musculoskeletal limitation. Healthy
controls were randomly invited to participate from two local
GP practices.
2.1. Statistical Analysis. We used SPSS (version 17.0) for
statistical analysis. Continuous variables are presented as
mean ± SD, and categorical data are presented as per-
centages. Continuous variables were assessed for normality
by the Kolmogorov-Smirnov test. An arbitrary level of 5%
statistical significance was used throughout (two tailed).
An independent t-test was used to measure diﬀerences
between CHF patients and healthy controls. All survivors
were followed for aminimum of 12months, and we therefore
give the probability of 12-month survival. Receiver operator
characteristic (ROC) curves were used to identify the value
of the strongest predictor variables of survival to 12 months.
We reported the area under the curve (AUC) with 95%
confidence intervals (CI), sensitivity, specificity, and optimal
cut-points in our ROC analysis. To define the optimal cut-
point, we used the point closest to the upper left corner of
the ROC curve, often known as the (0, 1) criterion.
All baseline variables (Table 1) were entered as potential
univariable predictors of mortality using Cox analysis, and
we adjusted for age, sex, BMI, aetiology of heart failure,
and severity of LV dysfunction (none, trivial, mild, mild-
to-moderate, moderate, moderate-to-severe, severe). Model
building was based on backward elimination (P value for
entry was <0.05; P value for removal >0.1). A multivari-
able Cox proportional hazards model using the backward
likelihood ratio method was used to identify independent
predictors of all-cause mortality from all significant candi-
date predictor variables. The outcome measure was all-cause
mortality. Kaplan-Meier survival curves were plotted for the
strongest candidate predictors; data were dichotomised by
optimal cut-points.
3. Results
423 patients with CHF (mean age 63 ± 12 years; 80%
males; LVEF 36± 6%; peak VO2 22.3 ± 8.1mL·kg−1·min−1;
VE/VCO2 slope 34± 8) were included in the study. Of these,
75%were taking ACE inhibitors, 77% beta blockers, and 67%
loop diuretics. Seventy eight healthy subjects (62% males;
age 61 ± 11 years) were recruited as a control group. The
healthy controls had a higher peak oxygen uptake, lower
VE/VCO2 slope, and lower VEqCO2 nadir (Table 1). Time
to VEqCO2 nadir was shorter in patients than controls (327
± 204 s versus 514 ± 187 s; P = 0.0001) but was similar as a
percentage of the total exercise duration in both groups (55±
23% versus 60±17%; P = 0.077). We performed a subgroup
analysis in 62 NYHA class III patients and found that the
time to VEqCO2 nadir was significantly lower (199 ± 59 s)
compared to other less symptomatic patients (344 ± 202 s;
P < 0.0001). We also performed a subgroup analysis by sex
and found that the time to VEqCO2 nadir was very similar
betweenmales (327±209 s) and females (328±94 s; P > 0.05;
n = 85).
In patients, time to VEqCO2 nadir correlated with age
(r = −0.17; P = 0.0001) and LVEF (r = 0.24; P = 0.0001)
but was not associated with BMI (r = 0.001; P = 0.98). Time
to VEqCO2 nadir correlated with peak oxygen uptake (r =
0.59; P = 0.001) and showed an inverse association with both
VE/VCO2 slope (r = −0.55; P = 0.001) and VEqCO2 nadir
(r = −0.56; P = 0.001). Scatter plots showing the association
between time to VEqCO2 nadir, peak oxygen uptake, and
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Table 1: Baseline clinical characteristics between CHF patients and
healthy controls.
Variable
(mean ± SD)
CHF
patients
Healthy
controls
P value∗
N 423 78 —
Males (%) 80 62 0.0001∗
Age (years) 63 (12) 61 (11) 0.529
BMI (kg·m−2) 28 (5) 26 (3) 0.001∗
LVEF (%) 36 (6) 60 (6) 0.0001∗
pVO2 (mL·kg−1·min−1) 22.3 (8.1) 36.2 (8.8) 0.0001∗
VE/VCO2 slope (full) 33.8 (7.7) 27.7 (3.0) 0.0001∗
VEqCO2 nadir 32.4 (6.2) 26.5 (3.0) 0.0001∗
Time to VEqCO2
nadir(s)
327 (514) 514 (187) 0.0001∗
AT (mL·kg−1·min−1) 15.2 (5.7) 23.4 (6.6) 0.0001∗
Peak RER 1.07 (0.10) 1.08 (0.06) 0.223
Exercise duration (s) 564 (250) 881 (256) 0.0001∗
Heart rate (rest)
(beats·min−1) 76 (15) 72 (12) 0.079
Heart rate (peak)
(beats·min−1) 136 (30) 165 (20) 0.0001
∗
Systolic BP (rest)
(mmHg)
137 (25) 148 (20) 0.0001∗
Systolic BP (peak)
(mmHg)
172 (36) 199 (22) 0.0001∗
Diastolic BP (rest)
(mmHg)
84 (15) 90 (9) 0.0001∗
Diastolic BP (peak)
(mmHg)
93 (22) 101 (21) 0.003∗
Loop diuretic (%) 67 — —
ACE-I (%) 75 — —
Beta-blocker (%) 77 — —
BMI: body mass index; LVEF: left ventricular ejection fraction; pVO2: peak
oxygen uptake; ACE-I: ACE inhibitor; peak RER: peak respiratory exchange
ratio; AT: anaerobic threshold; BP: blood pressure; ∗diﬀerences between
CHF and healthy controls, P < 0.05.
VE/VCO2 slope in patients and controls are shown in
Figures 1 and 2.
One hundred and eighteen patients (28%) died during
followup. The median followup in survivors was 8.6 ±
2.1 years. Univariable predictors of outcome derived from
CPET are shown in Table 2. With the exception of resting
heart rate, all candidate variables were significant univariable
predictors. The strongest univariable predictors of all-cause
mortality were peak oxygen uptake (χ2 = 53.0), VEqCO2
nadir (χ2 = 47.9), VE/VCO2 slope (χ2 = 31.7), and time
to VEqCO2 nadir (χ2 = 24.0). In a Cox multivariable
proportional hazards model adjusted for age, sex, BMI, and
severity of LV dysfunction, peak oxygen uptake (χ2 = 16.7;
HR = 0.91; 95% CI 0.88–0.95; P = 0.0001) and VEqCO2
nadir (χ2 = 17.9; HR = 1.12; 95% CI 1.04–1.20; P =
0.0001) were the most significant independent predictors of
mortality.
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Figure 1: Relation between time to VEqCO2 nadir and peak oxygen
uptake in patients with CHF and controls.
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Figure 2: Relation between time to VEqCO2 nadir and VE/VCO2
slope in patients with CHF and controls.
ROC curve analysis of the relation between time to
VEqCO2 nadir (and both VEqCO2 nadir and peak VO2)
and all-cause mortality at 12 months is shown in Figure 3.
Time to VEqCO2 nadir (AUC = 0.75; P < 0.0001; 95% CI
= 0.67–0.84; sensitivity = 81; specificity = 62; optimal cut-
point = 250 s); VEqCO2 nadir (AUC = 0.81; P < 0.0001;
95% CI = 0.74–0.89; sensitivity = 86; specificity = 62;
optimal cut-point = 33); peak VO2 (AUC = 0.76; P <
0.0001; 95% CI = 0.67–0.85; sensitivity = 86; specificity =
57; optimal cut-point = 20mL·kg−1·min−1) were similar in
their relation to all-cause mortality at 12 months. Optimal
cut-points determined from ROC analysis were used to
construct Kaplan-Meier survival curves for time to VEqCO2
nadir (Figure 4), VEqCO2 nadir (Figure 5), and peak VO2
(Figure 6).
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Table 2: Unadjusted univariable predictors of outcome (in order of Chi-square value).
Variables P value HR 95% CI Chi-square
Peak oxygen uptake 0.0001 0.891 0.862 0.920 53.0
VEqCO2 nadir 0.0001 1.095 1.068 1.122 47.9
VE/VCO2 slope 0.0001 1.060 1.041 1.079 31.7
Time to VEqCO2 nadir∗ 0.0001 0.705 0.523 0.905 24.0
Heart rate at peak exercise 0.0001 0.995 0.978 0.992 18.5
Systolic blood pressure (rest) 0.001 0.986 0.978 0.994 12.0
Diastolic blood pressure (rest) 0.02 0.977 0.963 0.991 9.3
Heart rate (rest) 0.744 1.002 0.990 1.014 0.1
HR: hazard ratio; 95% CI: 95% confidence intervals; ∗adjusted HR associated with 10 s increase in time to VEqCO2 nadir.
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Figure 3: Receiver operating characteristic curve showing value of
VEqCO2 nadir, time to VEqCO2 nadir, and peak oxygen uptake for
predicting all-cause mortality at 12 months. VEqCO2 nadir: AUC =
0.81; P < 0.0001; 95% CI = 0.74–0.89; sensitivity = 86; specificity =
62; optimal cut-point = 33; time to VEqCO2 nadir: AUC = 0.75;
P < 0.0001; 95% CI = 0.67–0.84; sensitivity = 81; specificity = 62;
optimal cut-point = 250 s; peak VO2: AUC = 0.76; P < 0.0001; 95%
CI = 0.67–0.85; sensitivity = 86; specificity = 57; optimal cut-point
= 20mL·kg−1·min−1.
4. Discussion
Wehave shown that the time to VEqCO2 nadir is significantly
lower in patients with CHF compared to controls. To our
knowledge, no previous study has evaluated the prognostic
value of time to VEqCO2 nadir. Sun and colleagues [12]
showed that the lowest VEqCO2 (VEqCO2 nadir) was the
most stable marker of ventilatory ineﬃciency in healthy
controls. Duringmaximal exercise testing, the VEqCO2 nadir
was achieved at around the ventilatory anaerobic threshold
and occurred during “moderate” exercise intensity. Both
VE and VCO2 are linearly related up to the ventilatory
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Figure 4: Kaplan-Meier survival curve showing time to VEqCO2
nadir-data dichotomised by optimal cut-points (<250 s; n = 170,
event free survival 61%;≥250 s n = 254 patients, event free survival
80%).
compensation point (VCP). Beyond this point (during heavy
to maximal exertion), an increase in VE relative to VCO2 is
dependent upon the fall in pH and PaCO2 [12].
The exaggerated ventilatory response of patients with
CHF is seen at the outset of exercise; that is, the VE/VCO2
slope is abnormal from the moment exercise starts. A wide
variety of factors has been proposed as the reason for
the increase in VE/VCO2 slope including an increased
dead space and resultant “wasted” ventilation [13–15], early
metabolic acidosis [16], and overactivation of chemorecep-
tors and ergoreceptors [17, 18]. The fall in the VEqCO2 at
the onset of exercise is at least in part due to the reduction
in fixed anatomical dead space ventilation as a proportion of
total ventilation at the onset of exercise, but the increase after
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Figure 5: Kaplan-Meier survival curve showing VEqCO2 nadir-
data dichotomised by optimal cut-points (<33 n = 252 patients,
event free survival 85%; ≥33 n = 171 patients, event free survival
54%).
the plateau phase is due to a non-CO2 stimulus to ventilation,
wheather lactate production or an alternative stimulus to
ventilation, such as the ergoreflex [9, 19]. The shorter time to
VEqCO2 nadir reflects the earlier onset (andmore important
influence of) the non-CO2 stimulus to ventilation in patients
with CHF.
We found a strong relation between the time to VEqCO2
nadir and mortality. The time to VEqCO2 nadir was
an important univariable predictor of all-cause mortality
although it was outperformed by peak oxygen uptake and
VEqCO2 nadir in a multivariable survival model. We have
previously shown that peak oxygen uptake [20] and VEqCO2
nadir [7] are independent predictors of all-cause mortality
in patients with CHF. Other investigators have also reported
similar findings [8, 21].
A limitation of our study is that we do not have test-retest
CPET data for individual patients/controls; therefore, we
cannot determine the reproducibility of the time to VEqCO2
nadir in either healthy or diseased populations.
Cardiopulmonary exercise testing provides two broad
types of prognostic variable: a measure of exercise capacity,
such as peak VO2, reflecting the complex relation between
pump, ventilator, and muscle extraction; and a measure of
the ventilatory response to exercise, such as the VE/Vco2
slope or time to VEqCO2 nadir, reflecting the abnormal
stimulus to ventilation in CHF. The time to VEqCO2 nadir
following maximal CPET was shorter in patients with CHF
than in normal subjects and is a predictor of subsequent
mortality.
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Figure 6: Kaplan-Meier survival curve showing peak VO2-data
dichotomised by optimal cut-points (<20mL·kg−1·min−1 n = 184
patients, event free survival 60%; ≥ 20mL·kg−1·min−1 n = 239
patients, event free survival 82%).
5. Clinical Messages
(i) Cardiopulmonary exercise testing is becoming
increasingly important for prescribing appropriate
exercise training volumes in patients with
cardiovascular disease including CHF.
(ii) The ventilatory response to exercise is abnormal
in patients with CHF compared to age-matched
controls.
(iii) Metabolic responses to exercise are important predic-
tors of risk and should be monitored prior to and
following a program of rehabilitation in patients with
CHF.
Conflict of interests
The authors declare that there is no conflict of interests.
Acknowledgment
This research received no specific grant from any funding
agency in the public, commercial, or not-for-profit sectors.
References
[1] G. J. Balady, R. Arena, K. Sietsema et al., “Clinician’s guide
to cardiopulmonary exercise testing in adults: a scientific
statement from the american heart association,” Circulation,
vol. 122, no. 2, pp. 191–225, 2010.
6 Pulmonary Medicine
[2] T. P. Chua, P. Ponikowski, D. Harrington et al., “Clinical cor-
relates and prognostic significance of the ventilatory response
to exercise in chronic heart failure,” Journal of the American
College of Cardiology, vol. 29, no. 7, pp. 1585–1590, 1997.
[3] A. Clark and A. Coats, “The mechanisms underlying the
increased ventilatory response to exercise in chronic stable
heart failure,” European Heart Journal, vol. 13, no. 12, pp.
1698–1708, 1992.
[4] L. Ingle, K. Goode, S. Carroll et al., “Prognostic value of the
VE/VCO2 slope calculated from diﬀerent time intervals in
patients with suspected heart failure,” International Journal of
Cardiology, vol. 118, no. 3, pp. 350–355, 2007.
[5] A. L. Clark, M. Volterrani, J. W. Swan, and A. J. S. Coats, “The
increased ventilatory response to exercise in chronic heart
failure: relation to pulmonary pathology,” Heart, vol. 77, no.
2, pp. 138–146, 1997.
[6] R. L. Bard, B. W. Gillespie, N. S. Clarke, T. G. Egan, and J. M.
Nicklas, “Determining the best ventilatory eﬃciency measure
to predict mortality in patients with heart failure,” Journal of
Heart and Lung Transplantation, vol. 25, no. 5, pp. 589–595,
2006.
[7] L. Ingle, R. Sloan, S. Carroll, K. Goode, J. G. Cleland, and A.
L. Clark, “Prognostic significance of diﬀerent measures of the
ventilation-carbon dioxide relation in patients with suspected
heart failure,” European Journal of Heart Failure, vol. 13, no. 5,
pp. 537–542, 2011.
[8] J. Myers, R. Arena, R. B. Oliveira et al., “The lowest VE/VCO2
ratio during exercise as a predictor of outcomes in patients
with heart failure,” Journal of Cardiac Failure, vol. 15, no. 9,
pp. 756–762, 2009.
[9] A. L. Clark, A. Poole-Wilson AP. A., and A. J. S. Coats,
“Relation between ventilation and carbon dioxide product in
patients with chronic heart failure,” Journal of the American
College of Cardiology, vol. 20, no. 6, pp. 1326–1332, 1992.
[10] N. B. Schiller, P. M. Shah, M. Crawford et al., “Recommenda-
tions for quantitation of the left ventricle by two-dimensional
echocardiography. American society of echocardiography
committee on standards, subcommittee on quantitation of
two-dimensional echocardiograms,” Journal of the American
Society of Echocardiography, vol. 2, no. 5, pp. 358–367, 1989.
[11] W. L. Beaver, K. Wasserman, and B. J. Whipp, “A new method
for detecting anaerobic threshold by gas exchange,” Journal of
Applied Physiology, vol. 60, no. 6, pp. 2020–2027, 1986.
[12] X. G. Sun, J. E. Hansen, N. Garatachea, T. W. Storer, and K.
Wasserman, “Ventilatory eﬃciency during exercise in healthy
subjects,” American Journal of Respiratory and Critical Care
Medicine, vol. 166, no. 11, pp. 1443–1448, 2002.
[13] K. Wasserman, Y. Y. Zhang, A. Gilt et al., “Lung function and
exercise gas exchange in chronic heart failure,” Circulation, vol.
96, no. 7, pp. 2221–2227, 1997.
[14] M. Guazzi, G. Reina, G. Tumminello, and M. D. Guazzi,
“Exercise ventilation ineﬃciency and cardiovascular mortality
in heart failure: the critical independent prognostic value of
the arterial CO2 partial pressure,” European Heart Journal, vol.
26, no. 5, pp. 472–480, 2005.
[15] J. R. Wilson and N. Ferraro, “Exercise intolerance in patients
with chronic left heart failure: relation to oxygen transport and
ventilatory abnormalities,” American Journal of Cardiology,
vol. 51, no. 8, pp. 1358–1363, 1983.
[16] J. Myers, A. Salleh, N. Buchanan et al., “Ventilatory mech-
anisms of exercise intolerance in chronic heart failure,”
American Heart Journal, vol. 124, no. 3, pp. 710–719, 1992.
[17] T. Tomita, H. Takaki, Y. Hara et al., “Attenuation of hyper-
capnic carbon dioxide chemosensitivity after postinfarction
exercise training: possible contribution to the improvement in
exercise hyperventilation,” Heart, vol. 89, no. 4, pp. 404–410,
2003.
[18] A. Ciarka, N. Cuylits, J. L. Vachiery et al., “Increased peripheral
chemoreceptors sensitivity and exercise ventilation in heart
transplant recipients,” Circulation, vol. 113, no. 2, pp. 252–257,
2006.
[19] A. L. Clark, P. A. Poole-Wilson, and A. J. S. Coats, “Exercise
limitation in chronic heart failure: central role of the periph-
ery,” Journal of the American College of Cardiology, vol. 28, no.
5, pp. 1092–1102, 1996.
[20] L. Ingle, K. K. Witte, J. G. F. Cleland, and A. L. Clark,
“Combining the ventilatory response to exercise and peak
oxygen consumption is no better than peak oxygen consump-
tion alone in predicting mortality in chronic heart failure,”
European Journal of Heart Failure, vol. 10, no. 1, pp. 85–88,
2008.
[21] E. A. Jankowska, T.Witkowski, B. Ponikowska et al., “Excessive
ventilation during early phase of exercise: a new predictor
of poor long-term outcome in patients with chronic heart
failure,” European Journal of Heart Failure, vol. 9, no. 10, pp.
1024–1031, 2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
